sevenTM
sevenTM is revolutionizing early drug discovery with AI-powered tools based on first principles, focusing on minimizing toxicity and side effects. Their platform identifies new drug candidates and novel indications for existing drugs in oncology and rare diseases, with promising compounds undergoing in vitro validation. The company excels in designing therapeutics for low population diseases, including those with untargetable protein targets. They collaborate with pharmaceutical R&D teams and researchers to design new candidates for clinical trials, leveraging their AI-powered drug discovery pipeline. Their technology includes toxicity prediction, protein structure modeling, candidate docking, and manufacturability prediction, validated through in-silico/in-vitro feedback loops. sevenTM aims to accelerate the discovery of low-toxicity drug candidates, as demonstrated by their work on pediatric Acute Myeloid Leukemia and protein structure modeling with quantum computing.
sevenTM
sevenTM is revolutionizing early drug discovery with AI-powered tools based on first principles, focusing on minimizing toxicity and side effects. Their platform identifies new drug candidates and novel indications for existing drugs in oncology and rare diseases, with promising compounds undergoing in vitro validation. The company excels in designing therapeutics for low population diseases, including those with untargetable protein targets. They collaborate with pharmaceutical R&D teams and researchers to design new candidates for clinical trials, leveraging their AI-powered drug discovery pipeline. Their technology includes toxicity prediction, protein structure modeling, candidate docking, and manufacturability prediction, validated through in-silico/in-vitro feedback loops. sevenTM aims to accelerate the discovery of low-toxicity drug candidates, as demonstrated by their work on pediatric Acute Myeloid Leukemia and protein structure modeling with quantum computing.